DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1093079
Title:
ERF is a Potential ERK-Modulated Tumor Suppressor in Prostate Cancer
Corporate Author:
Sloan Kettering Institute for Cancer Research New York NY United States
Report Date:
2018-10-01
Abstract:
Half of all prostate cancers contain an oncogenic gene fusion between the androgen-regulated upstream elements of the TMPRSS2-gene with the consequently upregulated ETS transcription factor ERG. Despite this high prevalence, detecting the presence of TMPRSS2-ERG in patients tumors has little-to-no useful clinical utility, in part due to a lack of understanding of its mechanisms of oncogenesis. I have characterized a gene, ERF, which functions as a putative tumor suppressor. I had hypothesized that ERF is outcompeted by the TMPRSS2-ERG gene product. Currently, I have identified how ERF and ERG compete with each other, and as a result, have opposing effects on cancer cell proliferation. I am currently now investigating the tumor suppressor function of ERF in prostate cancers lacking TMPRSS2-ERG.
Descriptive Note:
Technical Report,30 Sep 2017,29 Sep 2018
Pages:
0020
Distribution Statement:
Approved For Public Release;
File Size:
6.37MB
